CPC G01N 33/56977 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 31/4406 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); G01N 33/56972 (2013.01); G01N 33/57423 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); G01N 2333/70535 (2013.01); G01N 2333/70539 (2013.01); G01N 2333/70596 (2013.01); G01N 2800/52 (2013.01)] | 18 Claims |
1. A method of selecting a patient for combination therapy comprising entinostat and an anti-PD-1 antibody comprising:
providing a peripheral blood sample obtained from the patient, wherein the patient is diagnosed with a cancer;
measuring the number of cells in the peripheral blood sample which are CD14-positive, HLA-DR-high, and CD16-negative;
measuring the number of total peripheral blood mononuclear cells in the peripheral blood sample; and
administering the combination therapy if the percentage of the CD14-positive, HLA-DR-high, and CD16-negative cells relative to total peripheral blood mononuclear cells is greater than a pre-determined percentage; wherein the pre-determined percentage is at least about 5%.
|